SNG Insider Trading (Synairgen)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £1,173.69
Insider Selling (Last 12 Months): £377,948.20
Synairgen Share Price & Price History
Current Price: GBX 29.67
Price Change: ▲ Price Increase of +1.069 (3.74%)
As of 05/20/2022 03:20 PM ET
This is the golden age of investing in artificial intelligence!
From HiveSkill | Ad
A.I. is going to be one of the dominant themes over the next decade, as companies automate their businesses and use A.I. to remain competitive.
Invest in this red-hot industry at pre-IPO prices.
Synairgen Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
1/27/2022 | Bruce Campbell | Insider | Buy | 621 | GBX 189 | £1,173.69 | | |
8/12/2021 | John C Ward | Insider | Sell | 269,963 | GBX 140 | £377,948.20 | | |
The $193 Billion US-China War You Don't Know About
From Investing Trends | Ad
They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.
The US-China "Lithium War" Is Creating Opportunity
SEC Filings (Institutional Ownership Changes) for Synairgen (LON:SNG)
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold and flu; and LOXL2 inhibitor, which has completed Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) and non-alcoholic fatty liver diseases. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Read More on Synairgen
Today's Range
Now: GBX 29.67
50 Day Range
MA: GBX 24.48
52 Week Range
Now: GBX 29.67
Volume
427,277 shs
Average Volume
4,276,102 shs
Market Capitalization
£59.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Synairgen?